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Prior studies observing greater mortality in for-profit dialysis
units have not captured information about benchmarks of
care. This study was undertaken to examine the association
between profit status and mortality while achieving
benchmarks. Utilizing data from the US Renal Data System
and the Centers for Medicare & Medicaid Services’ end-stage
renal disease (ESRD) Clinical Performance Measures project,
hemodialysis units were categorized as for-profit or
not-for-profit. Associations with mortality at 1 year were
estimated using Cox regression. Two thousand six hundred
and eighty-five dialysis units (31 515 patients) were
designated as for-profit and 1018 (15 085 patients) as
not-for-profit. Patients in for-profit facilities were more likely
to be older, black, female, diabetic, and have higher urea
reduction ratio (URR), hematocrit, serum albumin, and
transferrin saturation. Patients (19.4 and 18.6%) in for-profit
and not-for-profit units died, respectively. In unadjusted
analyses, profit status was not associated with mortality
(hazard ratio (HR)¼ 1.04, P¼ 0.09). When added to models
with profit status, the following resulted in a significant
association between profit status (for-profit vs not-for-profit)
and increasing mortality risk: URR, hematocrit, albumin, and
ESRD Network. In adjusted models, patients in for-profit
facilities had a greater death risk (HR 1.09, P¼ 0.004). More
patients in for-profit units met clinical benchmarks. Survival
among patients in for-profit units was similar to not-for-profit
units. This suggests that in the contemporary era,
interventions in for-profit dialysis units have not impaired
their ability to deliver performance benchmarks and do not
affect survival.
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Since 1988, the number of end-stage renal disease (ESRD)
patients treated in dialysis units classified with the Centers for
Medicare & Medicaid Services (CMS) as ‘for-profit’
has progressively increased. Approximately 80% of prevalent
dialysis patients receive care from for-profit providers.1,2
Further, an association between clinical outcomes and
the profit status of the healthcare provider has been
reported.3–11 It has also been suggested that ESRD patients
are especially vulnerable to the implementation of
cost-efficiency measures that may under-utilize needed
services as a strategy to reduce costs in dialysis units.4,5 Cost
minimization may occur through the use of less skilled and
thus lower paid personnel, reduced staff to patient ratios,
increased patient throughput by shortening hemodialysis
times, use of cheaper disposables like dialyzers, reprocessing
and reusing disposables, decreased use of prospectively paid
laboratory tests, etc. The proposed causal pathway between
cost containment and increased mortality is through a
reduction in critical services.3,4
Support for these assertions was offered by two recent
analyses. In a study of 3569 US hemodialysis patients
receiving in-center hemodialysis between 1990 and 1993,
Garg et al.5 demonstrated that for-profit ownership as
compared with not-for-profit of dialysis facilities was
associated with increased mortality (relative risk¼ 1.20).
Subsequently, a meta-analysis reported that for-profit dialysis
centers were associated with an increased risk of death when
compared with not-for-profit centers (relative risk¼ 1.08).4
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Although these earlier studies adjusted for differences in
demographic features, they were unable to capture inform-
ation on intermediate measures related to dialysis processes
of care. This may be germane, as dialysis process measures
can be affected by cost reduction strategies, for example,
shorter dialysis times or cheaper dialyzers with lower dialysis
doses.12–14 Therefore, we posit that differences in dialysis
process measures should be apparent across provider types
based on profit status, and these differences are associated
with mortality risk. As the period of data collection in the
aforementioned studies, quantitative performance measures
have been implemented in Medicare-certified dialysis units.15
Performance benchmarking, facility profiling, and feedback
have been adopted and are associated with improved patient
outcomes.16 The current analysis was undertaken using a
more contemporary data set allowing the capture of key
dialysis unit characteristics, patient mortality, and critical
outcome measures that independently predict patient
mortality risk. It is possible that the relationships between
profit status and patient mortality have changed under an
environment of enhanced outcome disclosure and provider
accountability.17
RESULTS
Patient and dialysis unit characteristics
Three thousand seven hundred and three facilities and 46 600
patients were included in this analysis. Among dialysis units,
2685 were for-profit (72.5%) and 1018 (27.5%) were not-for-
profit. Among patients, 31 515 (67.6%) and 15 085 (32.4%)
received care in for-profit and not-for-profit dialysis units.
Patients in for-profit dialysis units were older (P¼ 0.002),
more likely to be female (P¼ 0.002), black (Po0.0001),
and have diabetes mellitus (Po0.0001) (Table 1). The
proportion of patients with comorbid conditions was similar
between the two groups, except for a higher proportion with
hypertension in the for-profit units (Po0.0001).
The proportion of patients using a prosthetic graft as
compared to autologous fistula was higher among patients
in for-profit as compared with not-for-profit units
(Po0.0001), whereas the proportion of patients using
percutaneous catheters was similar (P¼ 0.09). Patients in
for-profit units had a higher urea reduction ratio (URR),
dialysis time, hematocrit, serum albumin, transferrin satura-
tion, and serum ferritin (all Po0.0001). A larger proportion
of patients in for-profit units had URR X65% and
hematocrit X33% compared to those in not-for-profit units
(Po0.0001). The number of years on hemodialysis was
higher for patients in not-for-profit units. Although for-
profit units had a slightly lower number of dialysis stations
per unit (P¼ 0.0006), these units dialyzed a larger number of
patients (Po0.0001).
In 1994, 43.3 and 26.2% of patients achieved an URR of
X65% and a hematocrit of X33%, respectively (Table 2).
The proportion of patients achieving an URR or hematocrit
greater than these two thresholds increased each year to 79.8
and 70.3% (Po0.0001), respectively. The proportion of
patients with an albumin of X3.6 gm/dl also increased
during this time period from 73.9 to 79.8% (Po0.0001).
Patient survival
Over 1 year of follow-up, 19.4 and 18.6% of patients died
receiving care in for-profit and not-for-profit units, respec-
Table 1 | Clinical and demographic characteristics of patientsa
Variable
For-profit
(n=31 515)
Not-for-profit
(n=15 085) P-value
Age (years) 60.7 (15.2) 60.3 (15.6) 0.0021
Gender
Female 15 209 (48.3) 7045 (46.7) 0.0016
Male 16 298 (51.7) 8038 (53.3)
Race
White 16 273 (52.6) 8462 (57.1) o0.0001
Black 12 212 (39.4) 5009 (33.8) o0.0001
Other 2468 (8.0) 1354 (9.1) o0.0001
Diabetes mellitusb 11 692 (38.3) 5274 (36.0) o0.0001
Body mass index (kg/m2) 26.0 (6.5) 25.8 (6.5) 0.0543
Comorbid conditions
Heart disease 5662 (39.2) 2296 (39.7) 0.5081
Cerebrovascular
disease
1108 (7.7) 451 (7.8) 0.7583
Hypertension 10 937 (75.8) 4208 (72.8) o0.0001
Cancer 586 (4.1) 270 (4.7) 0.0508
COPD 840 (5.8) 362 (6.3) 0.2273
PVD 1888 (13.1) 779 (13.5) 0.4481
Number of years on
dialysis
3.2 (3.8) 3.5 (4.0) o0.0001
Vascular access type
Autologous fistula 2806 (26.0) 1149 (31.9) o0.0001
Prosthetic grafts 5661 (52.4) 1711 (46.1) o0.0001
Percutaneous catheter 2329 (21.6) 849 (22.9) 0.0942
Mean URR (%) 67.6 (8.9) 66.8 (9.2) o0.0001
Mean URR
X65% 67.5 64.0 o0.0001
o65% 32.5 36.0 o0.0001
Mean dialysis time (min) 201.6 (38.8) 199.0 (45.2) o0.0001
Mean albumin (g/dl) 3.9 (0.5) 3.8 (0.5) o0.0001
Mean hematocrit (%) 32.5 (4.0) 32.2 (4.6) o0.0001
Mean hematocrit
X33% 47.4 44.4 o0.0001
o33% 52.6 55.6 o0.0001
Mean transferrin
saturation (%)
29.0 (16.2) 27.4 (17.0) o0.0001
Mean ferritin (ng/ml) 471.3 (435.0) 407.7 (425.3) o0.0001
Mean no. of patients
treated (per dialysis unit)
130.9 (93.0) 104.9 (60.8) o0.0001
Mean no. of dialysis
stations (per dialysis unit)
20.8 (9.2) 21.2 (12.5) 0.0006
COPD=chronic obstructive pulmonary disease; PVD=peripheral vascular disease;
URR=urea reduction ratio.
aMean, median, or number (s.d. or %).
bDiabetes mellitus as primary cause of ESRD.
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tively. In a univariate model, profit status was not associated
with an increased mortality risk (hazard ratio (HR)¼ 1.04
among patients in for-profit units as compared to not-for-
profit units, P¼ 0.09; Table 3). However, the association
between profit status and mortality became significant when
URR, hematocrit, albumin, and ESRD Network were added
to profit status in separate models (P¼ 0.04, 0.04, 0.0009,
and 0.04, respectively). Variables tested that did not affect the
association between profit status and mortality included case
mix (age, gender, race, and diabetes mellitus), number of
years on dialysis, transferrin saturation, vascular access type,
comorbid conditions, body mass index, number of patients
treated, number of dialysis stations, and year of study.
In the multivariable model, controlling for all factors
influencing the association between profit status and
mortality, profit status was associated with an increased risk
of mortality. Patients in for-profit units as compared to not-
for-profit units had an increased death risk (HR¼ 1.09, 95%
confidence interval 1.03, 1.15, P¼ 0.004; Table 4). Other
significant predictors of mortality included increasing age,
white race, presence of diabetes mellitus, and later year of
study (all Po0.0001). Increasing URR, hematocrit, and
albumin were each associated with a decreased mortality risk
(Po0.0095, o0.0001, and 0.0001, respectively). ESRD Net-
works were also significantly associated with mortality. Age
demonstrated the greatest association with mortality
(w2¼ 1205), whereas profit status demonstrated the weakest
association (w2¼ 8.5).
Dialysis unit profit status did not interact with the
number of dialysis stations per facility (P¼ 0.29) or with year
of study (P¼ 0.84).
There were no substantive differences in results when
government facilities (both Federal and non-Federal) were
excluded from this analysis. In a univariate model, profit
status was not associated with mortality risk (HR¼ 1.03,
95% confidence interval 0.98, 1.09, among patients in for-
profit units as compared to not-for-profit units, P¼ 0.21). In
the multivariable model, profit status was associated with an
increased risk of mortality (HR¼ 1.06, 95% confidence
interval 1.01, 1.11, P¼ 0.03).
DISCUSSION
This study of dialysis units from 1995 to 2000 examines the
association between dialysis units’ profit status and patient
mortality. Significant demographic differences were observed
between patients in for-profit vs not-for-profit units. Patients
in for-profit units were more likely to be older and more
likely to be female, black, and have diabetes mellitus. A
greater proportion of patients in for-profit facilities met the
benchmarks of care for anemia management, dialysis
adequacy, and nutritional status.15 Survival for patients in
for-profit and not-for-profit units was not significantly
different.
The differences in characteristics of patients at baseline
includes factors that arguably are associated with mortality
risk.14,18,19 These baseline differences support the conclusion
that some form of selection bias is inherent in the assignment
of patients to dialysis units whether at the unit level, in that
Table 2 | Achievement of benchmarks of hemodialysis care by
year
URRX65% (%)* HCTX33% (%)* AlbuminX3.6 gm/dl (%)*
1994 43.3 26.2 73.9
1995 51.7 33.9 75.7
1996 61.0 39.7 77.9
1997 70.1 51.3 75.3
1998 74.8 56.7 77.7
1999 79.8 68.1 78.6
2000 85.2 70.3 79.8
HCT=hematocrit; URR=urea reduction ratio.
*All Po0.0001.
Table 3 | HR among patients dialyzing in for-profit as compared with not-for-profit dialysis units at one yeara
Variables HR 95% CI P-value N
Profit status only 1.04 0.99, 1.09 0.09 46 600
Profit status and case-mix variablesb 1.04 0.99, 1.09 0.08 44 355
Profit status and number of years on dialysis 1.04 0.99, 1.09 0.10 44 951
Profit status and albuminc 1.08 1.03, 1.13 0.0009 46 467
Profit status and URR 1.05 1.00, 1.10 0.04 45 468
Profit status and hematocrit 1.05 1.00, 1.10 0.04 39 004
Profit status and transferrin saturation 1.05 0.98, 1.12 0.18 25 033
Profit status and vascular access type (graft/fistula vs. catheter)d 1.08 0.98, 1.17 0.11 14 540
Profit status and comorbiditiese 1.03 0.96, 1.11 0.38 20 206
Profit status and BMI 1.06 0.99, 1.13 0.06 26 765
Profit status and ESRD Networks 1.05 1.00, 1.10 0.04 46 242
Profit status and number of patients treated during study period 1.02 0.97, 1.08 0.45 31 029
Profit status and total number of stations 1.04 0.99, 1.10 0.11 31 029
Profit status and year of study 1.04 0.99, 1.09 0.08 42 765
BMI, body mass index; CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; URR, urea reduction ratio.
aControlling for clinical, laboratory, and center-specific variables.
bCase-mix variables include age, gender, race (white vs other), and the presence of diabetes mellitus as the cause of ESRD.
cAlbumin analyzed using mathematical conversion of bromcresol purple to bromcresol green method.
dAvailable for years 1999 and 2000, only.
eTobacco use, cancer, cerebrovascular disease, congestive heart failure or coronary artery disease, hypertension, peripheral vascular disease, and chronic obstructive
pulmonary disease.
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locations of units is not random and baseline characteristics
of populations vary by region, or at the patient level, in that
certain patients are more likely to be assigned to a unit type
where both for-profit and not-for-profit are available.
Enhancing revenue per patient would hypothetically favor
the preferential exclusion of patients with an unfavorable case
mix with greater hospitalization and mortality risk, which
may potentially require more nursing time. The case mix
observed herein, however, suggests that exclusion of these
patients from for-profit units did not occur.
With regard to anemia management, dialysis dose, and
nutrition, for-profit units achieved the established bench-
marks among a greater proportion of patients than did not-
for-profit units. This is counterintuitive to an arguably
simplistic prediction that, if driven by financial interests
alone, patients in for-profit units would dialyze shorter times
to minimize labor costs or enhance patient throughput
reducing fixed expenses. Similarly, patients in for-profit units
had higher hematocrit values, higher transferrin saturation
values, and ferritin concentrations, and a greater proportion
had hematocrits X33%. Although the use of more
erythropoietin may be viewed as a variable revenue stream,2
increased use of iron supplements may lower erythropoietin
doses. However, higher transferrin saturations in for-profit
units suggest a similar vigilance to iron management. Finally,
although albumin concentrations reflecting both protein-
calorie nutrition and systemic inflammation20 were greater in
for-profit units, it is not clear that interventions by dialysis
providers may affect this parameter. Overall, the supposition
that the management of care in for-profit units that may be
directed at reducing costs affects the ability to achieve
adequacy in these intermediate outcomes is not supported by
these data.
The association between mortality and profit status is
complex. In the univariate model, profit status was not
associated with an increased mortality risk. In subsequent
models of profit status, the inclusion of individual process
measures that predict mortality revealed lower mortality in
the not-for-profit dialysis units. It should be noted that profit
status contributed the least to modeling the risk of death in
the multivariable model. Nevertheless, irrespective of its
minor contribution, profit status was associated with
mortality. The potentially conflicting results must be
interpreted in the context that the multivariable models that
control for processes of care may be ‘overadjusted’4 and
should be de-emphasized relative to the univariate models.
As the achievement of benchmarks of care are related to both
unit profit status as well as outcomes, they can be argued to
be either confounders or in the causal pathway between unit
status and mortality. Given the baseline case-mix differences,
unaccounted demographic and clinical differences between
patients in for-profit and patients in not-for-profit dialysis
units may contribute to differences in outcomes. An example
of such may be the presence of cardiovascular disease.
Inasmuch as patients in for-profit dialysis units were older
and more likely to be diabetic, it is conceivable that they had
a greater burden of cardiovascular disease. Although there
was no difference in recorded ‘heart disease’ on CMS’s
Medical Evidence Form (Form 2728), ascertainment bias may
be a limitation of this data source. Although profit status was
associated with mortality in adjusted models, but failed to be
associated in univariate models, it should be noted that these
findings are consistent with prior analyses,3–11 but to a lesser
degree.
The regional differences with respect to network support
the potential for uncontrolled confounding between location
and outcomes owing to differences in case mix or care
processes. As local market competition, costs, and insurance
payer mix vary substantially by region, clinical practices
outside of the dialysis units can likewise vary by geography.
These differences have been observed in other healthcare
industries,21 but not yet described for ESRD. It is also
possible that local non-ESRD services may influence survival
for hemodialysis patients. For example, achievement of
clinical performance benchmarks for diabetes mellitus varies
regionally.1 Similar regional variations in Medicaid reimbur-
Table 4 | Clinical and demographic associations with
mortality at one year (n=34 397)
HR 95% CI v2 P-value
Profita 1.09 1.03, 1.15 8.5 0.004
Age (per year increase) 1.04 1.03, 1.04 1205.0 o0.0001
Albumin (per increase
1 mg/dl)
0.45 0.43, 0.48 861.3 o0.0001
Race (white as
compared with
non-white)
1.37 1.30, 1.45 137.5 o0.0001
Diabetes mellitusb 1.25 1.19, 1.32 79.8 o0.0001
Hematocrit (per
increase 1 g/dl)
0.98 0.97, 0.98 60.8 o0.0001
Study year (per
increment of 1 year)
1.04 1.02, 1.05 21.8 o0.0001
URR (per increase 1%) 0.99 0.99, 0.99 12.0 0.0005
ESRD Networks
1 0.96 0.55
2 1.02 0.78
3 1.23 0.004
4 1.17 0.03
5 1.06 0.42
6 1.18 0.03
7 1.21 0.006
8 1.27 0.0009
9 1.09 0.23
10 0.98 0.74
11 1.05 0.48
12 1.08 0.28
13 1.14 0.08
14 1.07 0.38
15 1.19 0.01
16 1.11 0.17
17 1.17 0.04
18 Index —
CI=confidence interval; ESRD=end-stage renal disease; HR=hazard ratio; URR=urea
reduction ratio.
aFor-profit compared to not-for-profit (referent).
bDiabetes mellitus as primary cause of ESRD.
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sement may also play a role. Lastly, geographical differences
in proximity of dialysis units to tertiary or even secondary
care centers, which may reflect the availability of key services,
may also impact these results.
The variation in the magnitude and significance of the
relationship between profit status and outcomes in this and
prior studies must be noted. Although prior studies
demonstrated a significant relationship, the magnitude
varied. With regard to this study, the patient sample used
was similar, but more contemporary than those used in
earlier studies.5 Further, in comparison to others, we also
observed a higher proportion of patients in for-profit dialysis
units were black and had diabetes mellitus. It is not clear if
the difference in case mix reflects temporal trends in the
demographics of the ESRD population1 or differences in
sampling techniques. Although several previous studies
controlled for socioeconomic variables,4,5,7–9 they were not
able to adjust for the differences in dialytic processes of care.
Last, the more recent observational data examined in this
study incorporate the improvements in delivery of care and
mortality rate noted over recent years (mortality improved
from 32% in 1986 to 21.5% in 1996 to 19.3% in 2000 1).
The limitations of this analysis are typical of large
observational studies. First, it is impossible to impute
causality, so the findings are hypothesis-generating only.
Second, the potential for multiple levels of miscategorization
exists, including the dialysis units’ profit status, assignment of
patients to dialysis unit type, and comorbidities. The latter is
a concern as the assignment of comorbidities is based on
information incident to the development of ESRD only and
so limited by ascertainment biases. With respect to
comorbidities, a failure to note a comorbidity on the Medical
Evidence Form may not reflect its absence. With respect to
profit status exposure, if a dialysis unit converted (i.e. was
acquired) during the period of observation from not-for-
profit to for-profit, this would not be reflected in this
analysis. Similarly, if a patient were to move from one type of
unit to another, it would also not be reflected here. To
minimize the bias imposed by these and other sources of
misclassification, the observation period was limited to 1
year. In limiting the period, this analysis attempts to
minimize the length of time a patient is ‘exposed’ to a
different unit type than reflected in the analysis. Although the
more contemporary nature of these data enhance general-
izability as compared to prior reports, it should be noted that
as the completion of the collection of these data, the trend
toward increasing proportion of patients receiving their care
through for-profit units has continued. Finally, the impor-
tance of the baseline differences merits comment. Given
differences in those measurable demographic and laboratory
parameters known to effect mortality, the concern for non-
random differences in other unmeasured factors is raised.
With respect to the designation of units as for-profit and
non-profit and not-for-profit, it should be noted that these
labels do not reflect the heterogeneity that exists among units
of like type. Although this was a limitation of all prior
analyses,3–11 this study attempts to minimize this through the
inclusion of variables reflective of practical and potential
differences among units. Our data set did not allow us to
examine the type of caregivers (nurse vs patient care
technicians, clinical fellows, nurse practitioners) used, the
patient-to-staff ratio, ratio of practitioners to covered
facilities and/or hospitals, and forms of referral for
complications and access issues. In other studies, the mix
of non-physician caregivers has been favorable towards cost
minimization, that is, fewer nurses and higher patient-to-
staff ratios. However, the current study illustrates that profit
status as a potential surrogate for staffing patterns did not
adversely impact the provision of care benchmarks to
individual patients. Moreover, while the for-profit dialysis
units were more efficient in managing their capacity (higher
patients to treatment stations), their improved logistical
performance was achieved without compromise in their
delivery of care necessary to meet selected benchmarks.
Although the profitability of dialysis units is influenced by
their size with larger dialysis units being more profitable than
smaller dialysis units,2 the relationship between profit status
and mortality was unaffected by the size of the dialysis units.
One additional point regarding cause of death should be
addressed. It is noted that the distribution of cause of death
may potentially be non-random and related to geography
(e.g. accidental deaths, death due to AIDS, etc.). This analysis
utilizes all-cause death as an outcome; however, to obviate
concerns over the listed cause of death accurately reflecting
the actual cause. Arguably, while not all non-traumatic or
‘medical’ causes of death could be conceivably prevented by
diligent preventative care, the use of all-cause mortality
precludes the need for any subjective designation of cause of
death as such.
In summary, in a large, relatively contemporary cohort of
chronic hemodialysis patients, for-profit dialysis units
reported better outcomes for conventional ESRD perform-
ance measures than not-for-profit centers. Additionally,
hemodialysis patients in for-profit dialysis units had a similar
risk of mortality at 1 year as compared to those dialyzing in
not-for-profit units. When this risk was adjusted for the
greater proportion of patients achieving performance bench-
marks in for-profit units, the mortality risk among for-profit
units was greater, although the magnitude of this association
was modest compared to the death risk associated with more
conventional death risk factors like age, serum albumin, and
hematocrit. Although the relationship between profit status
and mortality is complex, we emphasize the results of the
analysis that does not overadjust for factors that are within
the scope of work of the dialysis facility and have a known
association with mortality such as dialysis dose. As for-profit
units consistently had greater success in achieving better
intermediate measures for sicker patients, but had similar
mortality outcomes, the question of what is the most
appropriate measure(s) for defining quality outcomes (i.e.
mortality or process measures such as dialysis dose and
anemia correction) must be raised, especially if reimburse-
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ment to providers is linked to outcomes. More plainly, the
results of this study raise the question as to whether mortality
differences seen in this and prior studies3–9 are reflective of
bias imposed by geographic localization of facilities or if the
intermediate outcomes currently identified are sufficient as
benchmarks of care.
Beyond the issue of for-profit vs not-for-profit provision
of ESRD care, there is increasing pressure from Medicare to
tie reimbursement for services to measures of quality. Given
that the process measures of care do not appear to correlate
with the outcome measure of survival, policy efforts to tie
reimbursement closer to these process measures should pause
until greater clarification of the relationship of process to
outcome measures can be established. Additional work is
required to discern the contributions of baseline differences
in patient populations, non-dialytic processes of care, and the
non-random geographical distribution of ownership of units
to more fully understand causality.
MATERIALS AND METHODS
Description of data set and definitions
Analyses were performed on a combined database developed using
datasets from the US Renal Data System and CMS’ ESRD Clinical
Performance Measures (CPM) from the cohort years 1995–2000. A
random sample of Medicare-eligible beneficiaries was identified
annually to provide nationally representative estimates of the quality
of care. The quality of care was assessed by profiling the percentage
of eligible patients who achieved selected benchmarks of hemodia-
lysis care.22,23 All Medicare-eligible, adult ESRD patients who were
alive and receiving hemodialysis on December 31 were eligible for
inclusion in the study sample for the following year. Information on
demographic characteristics, selected clinical parameters, and
dialysis performance were collected from the last 3 months of the
year preceding the study year. Information on demographic
characteristics, clinical parameters, laboratory parameters, dialysis
performance, and year of inclusion for each patient were obtained
from the ESRD CPM data set. Diabetes mellitus was coded as
present, if it was listed as the cause of ESRD. The number of years on
maintenance dialysis was defined as the time period between the
date hemodialysis began and January 1 of the sample year.
Data from the ESRD CPM Project were merged with data from
the standard analytic files of the US Renal Data System, a federal
registry database that contains information on demographic and
clinical characteristics of patients with ESRD. Where patients were
sampled in two different years, only the first year of their inclusion
in the ESRD CPM project was included. The standard analytic files
contain information on patients’ vital status and on the character-
istics of their hemodialysis facility. Profit status was coded as either
for-profit or not-for-profit based on information reported by the
dialysis units for the year of patient inclusion in the ESRD CPM
Project sample. Government-operated facilities were coded as not-
for-profit, initially. In subsequent sensitivity analyses, government
facilities were excluded.
Statistical analyses
The URR (measure of the fractional removal of urea per
hemodialysis treatment) was the measure of hemodialysis dose as
Kt/V was not captured in all years of the CMS study. Owing to the
possibility that some patients may have had multiple hemodialysis
vascular access types present during the sampled year, the current
hemodialysis vascular access type was defined as the vascular access
used during the last hemodialysis session in the 3-month data
collection period. Serum albumin concentrations were measured
using the bromcresol purple method and converted mathematically
to a value consistent with the bromcresol green method.24 Variables
with repeated measures from the ESRD CPM data set were averaged.
Comorbid conditions were utilized as recorded on Form no. 2728.
Body mass index was calculated by dividing weight in kilograms by
height in meters squared.
Demographic, clinical, and dialysis processes of care information
were compared for patients grouped by dialysis facility ownership
(for-profit vs not-for-profit) using the Student’s t-test and w2 test for
continuous and categorical variables, respectively. Cox’s propor-
tional hazards regression was used to estimate the association
between profit status and mortality risk. Start date was taken as the
1st day of the sampled year. Survival was calculated from the start
date to the date of death. Survival for patients who were either lost
to follow-up or transplanted during that year was censored at the
last recorded date of follow-up or transplantation. Patients who
were alive at the end of the year had survival recorded as 365 days.
The association between the facility profit status and mortality
was examined in a univariate model. Thereafter, bivariate models
were built with profit status and one additional variable or set of
variables included to examine their effect on the association between
profit status and mortality. A multivariate survival model was
applied using a forward stepwise method with the criteria for entry
and retention of Po0.05. Candidate variables for the final model
included age, gender, race, diabetes mellitus, body mass index, years
on dialysis, vascular access type, comorbidities, albumin, hemato-
crit, transferrin saturation, ferritin, URR, dialysis time, number of
dialysis stations, and number of patients treated. Variables that
confounded the association between profit status and mortality in
the bivariate models were forced into the multivariable model.
Variables were retained, if their addition to the model changed the
point estimate for the association between profit status and
mortality 410%. For all other variables, to minimize the impact
of missing data, additional variables were retained in the model if
significantly associated with mortality (Po0.05) and o10% of
patients had missing data for that variable.
All P-values are two-sided. All confidence intervals are 95%
intervals. The analyses were performed using SAS (version 8.2, SAS
Institute Inc., Cary, NC, USA). The authors (BC and LAS) had full
access to all the data in the study, take responsibility for the integrity
of the data, and the accuracy of the analysis.
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